RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis
Male osteoporosis is an increasingly recognized problem in aging men. A common cause of male osteoporosis is hypogonadism. Thousands of men with prostate cancer are treated with androgen deprivation therapy, a treatment that dramatically reduces serum testosterone and causes severe hypogonadism. Men...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Journal of Osteoporosis |
| Online Access: | http://dx.doi.org/10.4061/2011/941310 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548645817286656 |
|---|---|
| author | Alicia K. Morgans Matthew R. Smith |
| author_facet | Alicia K. Morgans Matthew R. Smith |
| author_sort | Alicia K. Morgans |
| collection | DOAJ |
| description | Male osteoporosis is an increasingly recognized problem in aging men. A common cause of male osteoporosis is hypogonadism. Thousands of men with prostate cancer are treated with androgen deprivation therapy, a treatment that dramatically reduces serum testosterone and causes severe hypogonadism. Men treated with androgen deprivation therapy experience a decline in bone mineral density and have an increased rate of fracture. This paper describes prostate cancer survivors as a model of hypogonadal osteoporosis and discusses the use of RANKL-targeted therapies in osteoporosis. Denosumab, the only RANKL-targeted therapy currently available, increases bone mineral density and decreases fracture rate in men with prostate cancer. Denosumab is also associated with delayed time to first skeletal-related event and an increase in bone metastasis-free survival in these men. It is reasonable to investigate the use of RANKL-targeted therapy in male osteoporosis in the general population. |
| format | Article |
| id | doaj-art-ea6c380ad11149f3819ce20c2cd68a76 |
| institution | Kabale University |
| issn | 2042-0064 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Osteoporosis |
| spelling | doaj-art-ea6c380ad11149f3819ce20c2cd68a762025-02-03T06:13:39ZengWileyJournal of Osteoporosis2042-00642011-01-01201110.4061/2011/941310941310RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male OsteoporosisAlicia K. Morgans0Matthew R. Smith1Division of Hematology/Oncology, Massachusetts General Hospital Cancer Center, POB 221, Boston, MA 02114, USADivision of Hematology/Oncology, Massachusetts General Hospital Cancer Center, POB 221, Boston, MA 02114, USAMale osteoporosis is an increasingly recognized problem in aging men. A common cause of male osteoporosis is hypogonadism. Thousands of men with prostate cancer are treated with androgen deprivation therapy, a treatment that dramatically reduces serum testosterone and causes severe hypogonadism. Men treated with androgen deprivation therapy experience a decline in bone mineral density and have an increased rate of fracture. This paper describes prostate cancer survivors as a model of hypogonadal osteoporosis and discusses the use of RANKL-targeted therapies in osteoporosis. Denosumab, the only RANKL-targeted therapy currently available, increases bone mineral density and decreases fracture rate in men with prostate cancer. Denosumab is also associated with delayed time to first skeletal-related event and an increase in bone metastasis-free survival in these men. It is reasonable to investigate the use of RANKL-targeted therapy in male osteoporosis in the general population.http://dx.doi.org/10.4061/2011/941310 |
| spellingShingle | Alicia K. Morgans Matthew R. Smith RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis Journal of Osteoporosis |
| title | RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis |
| title_full | RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis |
| title_fullStr | RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis |
| title_full_unstemmed | RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis |
| title_short | RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis |
| title_sort | rankl targeted therapies the next frontier in the treatment of male osteoporosis |
| url | http://dx.doi.org/10.4061/2011/941310 |
| work_keys_str_mv | AT aliciakmorgans rankltargetedtherapiesthenextfrontierinthetreatmentofmaleosteoporosis AT matthewrsmith rankltargetedtherapiesthenextfrontierinthetreatmentofmaleosteoporosis |